Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

Hareth Nahi; Saad Z. Usmani; Maria Victoria Mateos; Niels W.C.J. van de Donk; Albert Oriol; Torben Plesner; Nibedita Bandyopadhyay; Peter Hellemans; Brenda Tromp; Ivo Nnane; Donna Zemlickis; Ajai Chari; Philippe Moreau

doi:10.1080/10428194.2022.2148221

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

Hareth Nahi^*, Saad Z. Usmani, Maria Victoria Mateos, Niels W.C.J. van de Donk, Albert Oriol, Torben Plesner, Nibedita Bandyopadhyay, Peter Hellemans, Brenda Tromp, Ivo Nnane, Donna Zemlickis, Ajai Chari, Philippe Moreau

^*Kontaktforfatter

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

53 Downloads (Pure)

Originalsprog	Engelsk
Tidsskrift	Leukemia and Lymphoma
Vol/bind	64
Udgave nummer	2
Sider (fra-til)	468-472
ISSN	1042-8194
DOI	https://doi.org/10.1080/10428194.2022.2148221
Status	Udgivet - 2023

Dokumenter og links

10.1080/10428194.2022.2148221Licens: CC BY-NC-ND

Open Access VersionForlagets udgivne version, 1,11 MBLicens: CC BY-NC-ND

Citationsformater

Nahi, H., Usmani, S. Z., Mateos, M. V., van de Donk, N. W. C. J., Oriol, A., Plesner, T., Bandyopadhyay, N., Hellemans, P., Tromp, B., Nnane, I., Zemlickis, D., Chari, A., & Moreau, P. (2023). Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. Leukemia and Lymphoma, 64(2), 468-472. https://doi.org/10.1080/10428194.2022.2148221

@article{42e031f561ef4846b90ada504ca5d0cc,

title = "Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study",

author = "Hareth Nahi and Usmani, {Saad Z.} and Mateos, {Maria Victoria} and {van de Donk}, {Niels W.C.J.} and Albert Oriol and Torben Plesner and Nibedita Bandyopadhyay and Peter Hellemans and Brenda Tromp and Ivo Nnane and Donna Zemlickis and Ajai Chari and Philippe Moreau",

year = "2023",

doi = "10.1080/10428194.2022.2148221",

language = "English",

volume = "64",

pages = "468--472",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor & Francis",

number = "2",

}

Nahi, H, Usmani, SZ, Mateos, MV, van de Donk, NWCJ, Oriol, A, Plesner, T, Bandyopadhyay, N, Hellemans, P, Tromp, B, Nnane, I, Zemlickis, D, Chari, A & Moreau, P 2023, 'Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study', Leukemia and Lymphoma, bind 64, nr. 2, s. 468-472. https://doi.org/10.1080/10428194.2022.2148221

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. / Nahi, Hareth; Usmani, Saad Z.; Mateos, Maria Victoria et al.
I: Leukemia and Lymphoma, Bind 64, Nr. 2, 2023, s. 468-472.

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

TY - JOUR

T1 - Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab

T2 - part 3 of the open-label, multicenter, phase 1b PAVO study

AU - Nahi, Hareth

AU - Usmani, Saad Z.

AU - Mateos, Maria Victoria

AU - van de Donk, Niels W.C.J.

AU - Oriol, Albert

AU - Plesner, Torben

AU - Bandyopadhyay, Nibedita

AU - Hellemans, Peter

AU - Tromp, Brenda

AU - Nnane, Ivo

AU - Zemlickis, Donna

AU - Chari, Ajai

AU - Moreau, Philippe

PY - 2023

Y1 - 2023

U2 - 10.1080/10428194.2022.2148221

DO - 10.1080/10428194.2022.2148221

M3 - Comment/debate

C2 - 36593729

AN - SCOPUS:85145504293

SN - 1042-8194

VL - 64

SP - 468

EP - 472

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 2

ER -